Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: Systematic review and meta-analysis;Eficácia e segurança da terapia com idursulfase em pacientes com mucopolissacaridose tipo II, com e sem comparação com placebo: Revisão sistemática e metanálise

Cadernos de Saude Publica

Volumn 29, Issue SUPPL.1, 2013, Pages

  Alegra, Taciane ^a   Eizerik, Dauana Pitano ^a   de Cerqueira, Caio César Silva ^a   Pereira, Tiago V ^b,c   Dornelles, Alícia Dorneles ^a   Schwartz, Ida Vanessa Doederlein ^a,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Enzyme replacement therapy; Health technology evaluation; Mucopolysaccharidoses

Indexed keywords

IDURONATE 2 SULFATASE;

ENZYME REPLACEMENT; HUMAN; META ANALYSIS; MUCOPOLYSACCHARIDOSIS II; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ENZYME REPLACEMENT THERAPY; HUMANS; IDURONATE SULFATASE; MUCOPOLYSACCHARIDOSIS II; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887145411     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/0102-311X00017613     Document Type: Review

References (32)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421-52.
2. Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2007; 96:63-70.
3. Scarpa M. Mucopolysaccharidosis type II. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews. Seattle: University of Washington, Seattle; 1993-2007. http://www.ncbi.nlm.nih.gov/ books/NBK1116/.
4. Wraith JE. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2008; 97:76-8.
5. Schwartz IVD, Pinto LLC, Breda G, Lima L, Ribeiro MG, Mota JG, et al. Clinical and biochemical studies in mucopolysaccharidosis type II carriers. J Inherit Metab Dis 2009; 32:732-8.
6. de Camargo Pinto LL, Maluf SW, Leistner-Segal S, Zimmer da Silva C, Brusius-Facchin A, Burin MG, et al. Are MPS II heterozygotes actually asymptomatic? A study based on clinical and biochemical data, X-inactivation analysis and imaging evaluations. Am J Med Genet A 2001; 155A:50-7.
7. Schwartz IV, Souza CFM, Giugliani R. Tratamento de erros inatos do metabolismo. J Pediatr (Rio J) 2008; 84(4 Suppl):S8-19.
8. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2011.
9. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H. An emerging consensus on grading recommendations? Evid Based Med 2006; 11:2-4.
10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
11. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380-2.
12. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64:401-6.
13. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8:465-73.
14. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007; 90:329-37.
15. Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 2010; 99:18-25.
16. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011; 13:95-101.
17. Brands MM, Frohn-Mulder IM, Hagemans ML, Hop WC, Oussoren E, Helbing WA, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis 2013; 36;227-34.
18. Da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev 2011; (11):CD008185.
19. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-87.
20. Pereira TV, Patsopoulos NA, Salanti G, Ioannidis J. Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity. Res Synth Methods 2010; 1:149-61.
21. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002; (246):1-190.
22. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. American Thoracic Society statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-7.
23. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-18.
24. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-68.
25. Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Swiedler SJ, et al. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl 2005; 94:61-8.
26. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533-9.
27. Byers S, Rozaklis T, Brumfield KL, Ranieri E, Hopwood J. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidosis: characterization and basis of diagnostic test for MPS. Mol Genet Metab 1998; 65:285-90.
28. Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martínez SE, Zúñiga-González GM, Figuera LE, González-Noriega A, et al. Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 2000; 31:505-10.
29. Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evalulation of reliability of urine mucopolysaccaridosis screening by dimethylmethylene blue and berry spot tests. Clin Chim Acta 2004; 345:135-40.
30. Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L, et al. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis 2011; 34:749-54.
31. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 2012; 16:1-543.
32. Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009; 154:733-7.